Intraoperative mitomycin C and the corneal endothelium

Acta Ophthalmol Scand. 1998 Feb;76(1):80-2. doi: 10.1034/j.1600-0420.1998.760115.x.

Abstract

Purpose: Mitomycin-C (MMC) is a useful adjunct to high risk glaucoma surgery. No clinical data regarding the deleterious effect of mitomycin-C on the corneal endothelial cells are available.

Methods: Thirty eyes of 28 adult patients with high risk glaucomas were randomized to three groups. Group-I underwent a trabeculectomy alone, Group II, trabeculectomy with intraoperative 0.2mg/ml MMC and Group III, trabeculectomy with intraoperative 0.4mg/ml MMC. Preoperative and 3-month postoperative corneal endothelial cell counts were analysed.

Results: The percentage cell loss in Group I was 3.73+/-2.73%, in Group II 13.90+/-4.69% and in Group III 14.52+/-7.8%. Statistical analysis revealed a significant difference in cell loss between Group I and Group II and Group I and Group III, but not between Group II and Group III.

Conclusion: There is a significant loss of corneal endothelial cells three months after trabeculectomy with adjunctive MMC.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cell Count / drug effects
  • Chemotherapy, Adjuvant
  • Endothelium, Corneal / drug effects*
  • Endothelium, Corneal / pathology
  • Female
  • Glaucoma / drug therapy
  • Glaucoma / surgery*
  • Humans
  • Intraoperative Care
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage*
  • Mitomycin / adverse effects
  • Prospective Studies
  • Trabeculectomy*

Substances

  • Mitomycin